{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:21:23Z","timestamp":1789014083575,"version":"build-2803163510"},"reference-count":50,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy has emerged as an efficacious and life extending treatment modality with high response rates and durable remissions in patients with relapsed and refractory non-Hodgkin lymphoma (NHL), follicular lymphoma, and B-cell acute lymphoblastic leukemia (B-ALL) as well as in other diseases. Prolonged or recurrent cytopenias after CAR-T therapy have increasingly been reported at varying rates, and the pathogenesis of this complication is not yet well-understood but is likely contributed to by multiple factors. Current studies reported are primarily retrospective, heterogeneous in terms of CAR-Ts used and diseases treated, non-uniform in definitions of cytopenias and durations for end points, and vary in terms of recommended management. Prospective studies and correlative laboratory studies investigating the pathophysiology of prolonged cytopenias will enhance our understanding of this phenomenon. This review summarizes knowledge of these cytopenias to date.<\/jats:p>","DOI":"10.3390\/cancers14061501","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T03:34:13Z","timestamp":1647401653000},"page":"1501","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":94,"title":["Cytopenia after CAR-T Cell Therapy\u2014A Brief Review of a Complex Problem"],"prefix":"10.3390","volume":"14","author":[{"given":"Naman","family":"Sharma","sequence":"first","affiliation":[{"name":"Department of Hematology-Oncology, Baystate Medical Center, University of Massachusetts Medical School, Springfield, MA 100107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Reagan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hematology-Oncology, James P. Wilmot Cancer Institute, University of Rochester, Rochester, NY 14642, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane L.","family":"Liesveld","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hematology-Oncology, James P. Wilmot Cancer Institute, University of Rochester, Rochester, NY 14642, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood.2019000905","article-title":"High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy","volume":"134","author":"Hirayama","year":"2019","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR\u2013T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jtct.2021.09.016","article-title":"State of the CAR-T: Risk of infections with chimeric antigen receptor T-cell therapy and determinants of SARS-CoV-2 vaccine responses","volume":"27","author":"Meir","year":"2021","journal-title":"Transplant. Celluar Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11864-021-00920-6","article-title":"Allogeneic chimeric antigen receptor therapy in lymphoma","volume":"23","author":"Khurana","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_9","first-page":"40","article-title":"Primary analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed\/Refractory (R\/R) Indolent Non-Hodgkin Lymphoma (iNHL)","volume":"136","author":"Jacobson","year":"2020","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1200\/JCO.19.03237","article-title":"Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Zhou, H., Luo, Y., Zhu, S., Wang, X., Zhao, Y., Ou, X., Zhang, T., and Ma, X. (2018). The efficacy and safety of anti-CD19\/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4817-4"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1586\/ehm.11.62","article-title":"Late-onset neutropenia following rituximab therapy: Incidence, clinical featurs and possible mechanisms","volume":"4","author":"Tesfa","year":"2011","journal-title":"Exp. Rev. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/MD.0b013e3181f2caef","article-title":"Late-onset meutropenia after rituximab treatment: Case series and comprehensive review of the literature","volume":"89","author":"Wolach","year":"2010","journal-title":"Medicine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1056\/NEJM200306263482620","article-title":"Neutropenia in patients treated with rituximab","volume":"348","author":"Voog","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1046\/j.1365-2141.2003.04385.x","article-title":"Delayed onset neutropenia associated with rituximab therapy","volume":"121","author":"Chaiwatanatorn","year":"2003","journal-title":"Br. J. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.3324\/haematol.11031","article-title":"Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery","volume":"92","author":"Terrier","year":"2007","journal-title":"Haematologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/art.10764","article-title":"The relationship of FcgamaRIIIa genotype to degree of B-cell depletion by rituximab in the treatment of systemic lupus erythematous","volume":"48","author":"Anolik","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1080\/10428194.2021.1948037","article-title":"Late onset neutropenia after rituximab and obinutuzumab treatmet-characteristics of a class-effect toxicity","volume":"62","author":"Shimony","year":"2021","journal-title":"Leuk. Lymph."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/sj.bmt.1704467","article-title":"Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin\u2019s lymphoma","volume":"33","author":"Lemieux","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41409-020-01120-w","article-title":"The 46th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Poster Session (P001-P706, Abstract -P096)","volume":"55","author":"Iqbal","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_23","first-page":"238","article-title":"Characterisation of Early and Late Cytopenias in Lymphoma Patients following Treatment with antiCD19 CAR-T Therapy","volume":"Volume 55","author":"Hockings","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.3324\/haematol.2020.254045","article-title":"Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma","volume":"106","author":"Strati","year":"2021","journal-title":"Haematologica"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1080\/10428194.2019.1697814","article-title":"Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)","volume":"61","author":"Nahas","year":"2020","journal-title":"Leuk. Lymph."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: A model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"702644","DOI":"10.3389\/fonc.2021.702644","article-title":"New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Juluri, K.R., Wu, Q.V., Voutsinas, J., Hou, J., Hirayama, A.V., Mullane, E., Miles, N., Maloney, D.G., Turtle, C.J., and Bar, M. (2021). Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. Blood Adv.","DOI":"10.1182\/bloodadvances.2020004142"},{"key":"ref_32","first-page":"2049","article-title":"Abstract 2049: Cytokines associated with prolonged Cytopenia after axicabtagene ciloleucel in patients with refractory large B-cell lymphoma","volume":"80","author":"Strati","year":"2020","journal-title":"Clin. Res. (Exclud. Clin. Trials)"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Tvedt, T.H.A., Vo, A.K., Bruserud, O., and Reikvam, H. (2021). Cytokine release syndrome in the immunotherapy of hematological malignancies: The biology behind and possible clinical consequences. J. Clin. Med., 10.","DOI":"10.3390\/jcm10215190"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.20892\/j.issn.2095-3941.2021.0087","article-title":"Focused evaluation of the roles of macrophages in chimeric antigen receptor (CAR) T cell therapy associated cytokine release syndrome","volume":"18","author":"Guo","year":"2021","journal-title":"Cancer Biol. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1182\/bloodadvances.2021004554","article-title":"Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy","volume":"5","author":"Miller","year":"2021","journal-title":"Blood Adv."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1200\/JCO.2016.71.6712","article-title":"Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma","volume":"35","author":"Gibson","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1038\/s41467-020-16805-5","article-title":"Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant","volume":"11","author":"Mouhieddine","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor\u2013modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1038\/s41409-020-01006-x","article-title":"G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory\/relapsed B-cell lymphoma","volume":"55","author":"Galli","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"E20","DOI":"10.1002\/ajh.25664","article-title":"Successful treatment of marrow failure after CARTs for myeloma by the infusion of cryopreserved stem cells","volume":"95","author":"Yan","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1097\/HS9.0000000000000545","article-title":"Hematologic Rescue of CAR T-cell-mediated Prolonged Pancytopenia Using Autologous Peripheral Blood Hematopoietic Stem Cells in a Lymphoma Patient","volume":"5","author":"Sieg","year":"2021","journal-title":"HemaSphere"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"101287","DOI":"10.1016\/j.beha.2021.101287","article-title":"Toxicities associated with adoptive cellular therapies","volume":"34","author":"Hansen","year":"2021","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR-T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Trasnplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EA)","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1182\/blood-2021-154037","article-title":"Real-life CAR-T cell treatment in large B-cell lymphomas indicates that Axi-Cel and Tisa-Cel have similar outcomes, but long-term cytoepnia is an emerging problem","volume":"138","author":"Chiappella","year":"2021","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1182\/blood-2021-149738","article-title":"Cytopenias in CAR-T cell therapy and use of transfusion resources in adult patients with lymphporliferative disorders","volume":"138","author":"Mezquita","year":"2021","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1182\/blood-2021-151114","article-title":"Complete versus incomplete hematologic recovery after CAR T cell therapy: Implications for relapse free survival and overall survival in pediatric and young adult patients with relpased\/refractory B-ALL","volume":"138","author":"Lerman","year":"2021","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2021-146119","article-title":"Barriers to enrollment in clinical trials in patients with aggressive B-cell non-Hodgkin lymphoma that progressed after anti-CD19 CART cell therapy","volume":"183","author":"Bezerra","year":"2021","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1182\/blood-2021-151766","article-title":"Bendamustine is a safe and effective regimen for lymphodepletion before tisagenlecleucel in patients with large B cell lymphomas","volume":"138","author":"Ghilardi","year":"2021","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/6\/1501\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:36:57Z","timestamp":1760135817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/6\/1501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["cancers14061501"],"URL":"https:\/\/doi.org\/10.3390\/cancers14061501","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,15]]}}}